Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND)

INTRODUCTION Optimal blood pressure, glycemic and lipid control are of utmost importance to minimize the incidence and the progression of chronic renal and cardiovascular complications in patients with diabetes mellitus type 2. Whether angiotensin converting enzyme (ACE) inhibitors alone or combined to calcium channel blockers (CCB) may further reduce the incidence and progression of chronic complications is worth investigating.

AIMS The primary aim of this study is to assess whether at comparable levels of optimal blood pressure and metabolic control, the ACE inhibitor delapril alone or in combination with the dihydropyridine CCB manidipine slow the rate of glomerular filtration rate (GFR) decline as compared with placebo plus conventional antihypertensive therapy in patients with diabetes mellitus type 2 and hypertension. The secondary aim of this study is to assess the effects of delapril and manidipine on the incidence of major cardiovascular events (acute myocardial infarction, ictus or stroke, heart failure requiring hospitalization, revascularization, amputation and cardiovascular mortality).

STUDY POPULATION 342 hypertensive type 2 diabetes patients with normo- or micro-albuminuria. STUDY DESIGN This is a multicenter, prospective, randomized, double-blind, placebo-controlled study. After a 12-week baseline period in which prohibited antihypertensive treatments (ACE inhibitors, angiotensin II receptor antagonists or dihydropyridine calcium channel blockers) will be discontinued, patients will be stratified according to their urinary albumin excretion rate in normo- and micro-albuminuric and then randomized to delapril alone (30 mg/day), delapril (30 mg/day) combined with manidipine (10 mg/day) or placebo given once daily in the morning for at least three years. During the study, systolic and diastolic blood pressure in all treatments groups will be maintained ≤ 120 and 80 mmHg respectively, with fixed doses of study treatments and flexible doses of permitted antihypertensive therapy (diuretics, beta blockers, alfa blockers, centrally acting adrenergic blockers. Blood pressure, blood glucose concentrations and urinary albumin excretion rate will be monitored every three months. Serum lipid concentrations and GFR (estimated with the iohexol plasma clearance) will be measured every six months.

Primary and Secondary Variables. The primary efficacy variable of this study is the rate of GFR decline. The secondary efficacy variable will be the incidence of major cardiovascular events (acute myocardial infarction, ictus or stroke, heart failure requiring hospitalization, revascularization, amputation and cardiovascular mortality).

Inclusion criteria

• Age ≥ 40 years
• History of diabetes mellitus type 2 for at least three months with stable antidiabetic treatment
• Systolic and/or diastolic blood pressure ≥ 135 or 85 mmHg, respectively. In alternative, antihypertensive therapy regardless of blood pressure values
• Serum creatinine ≤ 1.5 mg/dL
• Urinary albumin excretion rate < 200 µg/min
• Written informed consent for the trial participation.

Exclusion criteria

• Clinical or histological evidence of non-diabetic renal disease, including vascular disease of the kidney, obstructive uropathy, prostatic hypertrophy or incomplete bladder emptying
• Transplanted kidney
• Moderate to severe chronic heart failure (III-IV stage according to the NYHA classification).
• Cerebral hemorrhage, stroke or transient ischemic attack within three months prior to the trial enrolment
• Myocardial infarction within three months prior to the trial enrolment
• Unstable angina pectoris
• Mitral valve stenosis, aortic stenosis or hypertrophic cardiomyopathy
• Secondary (e.g., Cushing disease, phaeochromocytoma, etc.) or severe refractory hypertension
• Poor glycemic control (HbA1c>11%)
• Connective tissue or autoimmune disease
• Hereditary angioneurotic edema
• Clinically relevant electrolyte imbalance (e.g., serum potassium > 5.5 mmol/L)
• Clinically relevant hematological disorders
• Anemia with hemoglobin concentrations < 10 g/dL
• Serious hepatic disease
• Pregnancy or lactating or planning a pregnancy
• Women of childbearing potential without following a scientifically accepted form of contraception
• Any other serious or terminal concomitant disease
• Any condition which may interfere with the absorption of the study treatments
• Any concomitant treatment with ACE inhibitors, angiotensin II blockers, calcium channel blockers, potassium sparing diuretics
• Chronic treatment with nonsteroidal antiinflammatory drugs, antidepressants and neuroleptics, lithium, cimetidine, immunosuppressive and/or antineoplastic drugs, chronic systemic glucocorticoid therapy more than 7 consecutive days in one month, antiarrhythmic drugs (e.g., chinidin, procainamide), anesthetics/narcotics
• History of hypersensitivity to delapril or other ACE inhibitors, manidipine or other dihydropyridine CCBs
• Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the trial
• Evidence of an uncooperative attitude
• Any evidence that allows predicting that the patient will not be able to complete the trial follow-up.